Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jun 9;19(12):7094.
doi: 10.3390/ijerph19127094.

New Advances in Cervical Cancer: From Bench to Bedside

Ottavia D'Oria  1 , Giacomo Corrado  2 , Antonio Simone Laganà  3 , Vito Chiantera  3 , Enrico Vizza  4 , Andrea Giannini  1
Affiliations
Editorial

New Advances in Cervical Cancer: From Bench to Bedside

Ottavia D'Oria et al. Int J Environ Res Public Health. .

Abstract

Cervical cancer is the most common gynecologic malignancy and the fourth most common cancer in women worldwide. Over the last two decades, minimally invasive surgery (MIS) has emerged as the mainstay in the surgical management of early-stage cervical cancer, bringing advantages such as a lower operative morbidity and shorter hospital stay compared to open surgery, while maintaining comparable oncologic outcomes in numerous retrospective studies. Considering oncological patients, it is mandatory to assess the oncological outcomes and safety of this type of surgery. Moreover, there are different future outlooks on cervical cancer therapy, based on immunotherapy, target therapy, and poly-ADP-ribose polymerases (PARP) inhibitors in combination with each other, and in combination with standard chemotherapy and radiotherapy. The goal is to find an approach that is as personalized as possible.

Keywords: cancer therapy; cervical cancer; gynecological cancer surgery; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Arbyn M., Weiderpass E., Bruni L., de Sanjosé S., Saraiya M., Ferlay J., Bray F. Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. Lancet Glob. Health. 2020;8:e191–e203. doi: 10.1016/S2214-109X(19)30482-6. - DOI - PMC - PubMed
    1. Bogani G., Sopracordevole F., Di Donato V., Ciavattini A., Ghelardi A., Lopez S., Simoncini T., Plotti F., Casarin J., Serati M., et al. High-risk HPV-positive and -negative high-grade cervical dysplasia: Analysis of 5-year outcomes. Gynecol. Oncol. 2021;161:173–178. doi: 10.1016/j.ygyno.2021.01.020. - DOI - PubMed
    1. Scioscia M., Noventa M., Palomba S., Laganà A.S. Effect of the COVID-19 pandemic on oncology screenings: It is time to change course. BJOG. 2021;128:2213–2214. doi: 10.1111/1471-0528.16857. - DOI - PMC - PubMed
    1. Uwins C., Patel H., Bhandoria G.P., Butler-Manuel S., Tailor A., Ellis P., Chatterjee J. Laparoscopic and robotic surgery for endometrial and cervical cancer. Clin. Oncol. 2021;33:e372–e382. doi: 10.1016/j.clon.2021.05.001. - DOI - PubMed
    1. Cibula D., Pötter R., Planchamp F., Avall-Lundqvist E., Fischerova D., Haie-Meder C., Köhler C., Landoni F., Lax S., Lindegaard J.C., et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer. Virchows Arch. 2018;472:919–936. doi: 10.1007/s00428-018-2362-9. - DOI - PubMed

Publication types

Substances